May 18, 2024
Targeted Protein Degradation - New Modalities and Design Technologies
Join us for our upcoming webinar on targeted protein degradation. Scheduled for June 20, 2024, this event is set to bring together leading experts Bernhard Fasching, PhD, VP Chemistry at Monte Rosa Therapeutics, and Benedict Cross, PhD, CTO at PhoreMost Therapeutics.
Together, they will explore promising new modalities gaining traction in drug discovery and unveil strategies and technologies aimed at targeting previously "undruggable" diseases.
This session is perfect for both seasoned researchers and newcomers to the field, offering insights that will enrich your understanding of drug discovery's latest advancements. Don’t miss this opportunity to engage with industry leaders and deepen your knowledge. Reserve your free seat now or register to receive a link to the on-demand recording and watch it at your convenience.
Thursday, June 20, 2024, at 8:00 AM (PDT) 11:00 AM Eastern (EDT) 4:00 PM (BST)
Featuring these leading scientists...
Bernhard Fasching, PhD
VP Chemistry, Monte Rosa Therapeutics
Graduated from the University of Dortmund and the Max Planck Institute for Kohlenforschung in 2007 in Total Synthesis with Prof. Fuerstner followed by a Post-Doc experience at Memorial Sloan Kettering working on glycopeptide synthesis with Prof. Danishefsky. Ever since, he has been working on the discovery and development of novel pharmacologically active molecules and principles for Hoffmann-La Roche and for a number of biotech companies in the areas of neuroscience, oncology and rare diseases. He has successfully lead drug discovery programs, using medicinal chemistry to advance molecules to patients. More recently, he has put a focus on the creation of biotech platforms centered around novel modes of action such as molecular glue degraders. Currently he is the head of chemistry at Monte Rosa Therapeutics leading the medicinal chemistry teams in drug discovery as well as the platform group with the aim to understand and employ the molecular mechanisms of ternary com.
Benedict Cross, PhD
CTO, PhoreMost Therapeutics
The current Chief Technology Officer at PhoreMost, a drug discovery company based in Cambridge, UK. He is a pioneer in the use of programmed mini-protein perturbagens to uncover new drug targets and has applied this in the protein degradation field in particular. Ben’s research interests are in protein biogenesis, proteostasis, TPD and functional genomic screening.